The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

Heart failure (HF) is a significant cause of morbidity and mortality worldwide. Circulating
biomarkers reflecting pathophysiological pathways involved in HF development and …

Diagnosing heart failure is often difficult due to the non‐specific nature of symptoms, which
can be caused by a range of medical conditions. Natriuretic peptides (NPs) have been …

Natriuretic peptides, brain (B-type) natriuretic peptide (BNP) and N-terminal prohormone of
brain natriuretic peptide (NT-proBNP) are globally and most often used for the diagnosis of …

Investigations into the mixed muscle–secretory phenotype of cardiomyocytes from the atrial
appendages of the heart led to the discovery that these cells produce, in a regulated …

Natriuretic peptide [NP; B‐type NP (BNP), N‐terminal proBNP (NT‐proBNP), and
midregional proANP (MR‐proANP)] concentrations are quantitative plasma biomarkers for …

Currently, brain natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) are widely
used as diagnostic biomarkers for heart failure (HF) and cardiac dysfunction in clinical …

Background: Hereditary transthyretin-mediated (hATTR) amyloidosis is a rapidly
progressive, multisystem disease that presents with cardiomyopathy or polyneuropathy. The …

Background and Purpose: Natriuretic peptides have led the way as a diagnostic and
prognostic tool for the diagnosis and management of heart failure (HF). More recent …

2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American
College of Cardiology Foundation/American Heart Association Task Force on Practice …